← ANALYST RATINGS · TIPRANKS
NeoGenomics (NEO): analyst forecast and price target
Analyst consensus
Strong Buy6 Buy2 Hold0 Sell
Ratings of 8 analysts in the last 3 months12-month forecast
Based on 8 price targets given in the last 3 months, the average target is $21.50, the highest $28.00, the lowest $19.00. The average is +29.1% from the last price of $16.65.
Analyst ratings 13
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Lu Li★★★★★★★★★★#5185 · hits 80% · avg +11.8% | UBS | — | Hold | — | Reiterated | 07.10.26on TipRanks Oct 8 03:20 | −3.0%next day +0.7% · 5 days +6.7% | ↗ |
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $21.00 → $17.00−19.0% | Hold | +2.1% | Reiterated | 07.10.26on TipRanks 11:05 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $20.00 → $16.50−17.5% | Hold | −0.9% | Reiterated | 07.10.26on TipRanks 11:05 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $20.50 → $16.50−19.5% | Hold | −0.9% | Reiterated | 07.10.26on TipRanks 11:05 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $20.00 → $16.50−17.5% | Hold | −0.9% | Reiterated | 07.10.26on TipRanks 11:05 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $21.50 → $18.00−16.3% | Hold | +8.1% | Downgrade | 07.10.26on TipRanks 11:05 | — | |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $20.50 → $17.50−14.6% | Hold | +5.1% | Reiterated | 07.10.26on TipRanks 11:05 | — | |
| Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% | Bank of America Securities | $16.00 → $20.00+25.0% | Hold | +20.1% | Reiterated | 06.10.26on TipRanks Oct 7 04:55 | −14.3%next day −3.0% · 5 days +1.1% | ↗ |
| Michael Matson★★★★★★★★★★#1853 · hits 50% · avg +6.0% | Needham | $19.00 → $22.00+15.8% | Buy | +32.1% | Reiterated | 06.10.26on TipRanks 08:25 | −14.3%next day −3.0% · 5 days +1.1% | ↗ |
| David Westenberg★★★★★★★★★★#602 · hits 56% · avg +17.3% | Piper Sandler | $21.00 | Buy | +26.1% | Reiterated | 06.10.26on TipRanks 07:15 | −14.3%next day −3.0% · 5 days +1.1% | ↗ |
| Matt Larew★★★★★★★★★★#816 · hits 63% · avg +19.3% | William Blair | — | Hold | — | Reiterated | 06.10.26on TipRanks 07:10 | −14.3%next day −3.0% · 5 days +1.1% | ↗ |
| Bruce Jackson★★★★★★★★★★#12272 · hits 38% · avg −9.8% | Benchmark Co. | $16.00 → $20.00+25.0% | Buy | +20.1% | Reiterated | 06.10.26on TipRanks 06:55 | −14.3%next day −3.0% · 5 days +1.1% | ↗ |
| Mark Massaro★★★★★★★★★★#2635 · hits 40% · avg +5.7% | BTIG | $28.00 | Buy | +68.2% | Upgrade | 06.10.26on TipRanks 06:05 | −14.3%next day −3.0% · 5 days +1.1% | ↗ |
| William Bonello★★★★★★★★★★#152 · hits 66% · avg +35.0% | Craig-Hallum | $17.00 → $19.00+11.8% | Buy | +14.1% | Reiterated | 29.07.26on TipRanks 10:39 | +15.5%next day +2.3% · 5 days −2.5% | ↗ |
| Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% | TD Cowen | $19.00 | Buy | +14.1% | Reiterated | 28.07.26on TipRanks Jul 29 01:50 | +1.7%next day +15.5% · 5 days +17.5% | ↗ |
| Unknown Analyst | Stephens | $15.50 | Buy | −6.9% | Reiterated | 29.04.26on TipRanks 09:35 | −0.6%next day +2.4% · 5 days −3.9% | ↗ |
| Puneet Souda★★★★★★★★★★#2942 · hits 45% · avg +4.1% | Leerink Partners | $25.00 | Buy | +50.2% | Upgrade | 29.04.26on TipRanks 06:25 | −0.6%next day +2.4% · 5 days −3.9% | ↗ |
| Unknown Analyst | Jefferies | $15.00 | Buy | −9.9% | Reiterated | 18.02.26on TipRanks 14:15 | −10.8%next day −2.2% · 5 days −5.3% | ↗ |
| Unknown Analyst | Guggenheim | — | Hold | — | Reiterated | 17.02.26on TipRanks Feb 18 07:35 | +0.4%next day −10.8% · 5 days −16.3% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering NeoGenomics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $18.33 at a price of $18.36 (−0.1%); now: $21.50 at $16.65 (+29.1%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 0 | 0 | 0 | 1 |
| Buy | 4 | 5 | 7 | 9 | 8 | 5 |
| Hold | 5 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 28.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.06 (from $0.04 to $0.07). Last quarter: $0.05.
Sales
Next quarter’s sales estimate — $207M (from $204M to $209M). Last quarter: $202M.
Best top-analyst consensus in the sector · Healthcare
About NeoGenomics
- CEO: Anthony Zook
- Employees: 2,500
- 9490 NeoGenomics Way, Fort Myers, FL, 33912, US
- www.neogenomics.com
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
Data from the stock’s TipRanks forecast page, read 8 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗